American Shared Hospital Services (AMS) — customer relationships and commercial profile

Thesis: American Shared Hospital Services (AMS) rents and operates advanced radiosurgery and radiation therapy systems to hospitals and cancer centers, monetizing through long-term, fee‑per‑use and revenue‑sharing leases for high‑capex equipment (Gamma Knife and PBRT) and ancillary services (installation, reimbursement and marketing support). For investors, AMS is a capital‑light equipment financier and service operator whose revenue is driven by procedure volumes under multi‑year contracts and concentrated hospital counterparty exposure.

If you want a consolidated view of AMS customer relationships and contract dynamics, visit https://nullexposure.com/ for the full platform.

How AMS makes money and what that implies for revenue quality

AMS’s core business is to place expensive radiosurgery systems at provider sites under typically ten‑year contracts that are either fee‑per‑use or revenue‑sharing arrangements. Fee‑per‑use revenues are recognized when procedures occur, so top‑line depends on procedure throughput and contracted per‑case rates, while revenue‑sharing contracts tie AMS directly to the economics of a customer’s service line. The company also provides equipment, installation, and commercialization services, creating recurring service revenue and lock‑in.

Key commercial characteristics:

Contracting posture: long‑term and usage‑based. The company’s leasing agreements are typically ten years and structured around usage-based fees or shared revenue.
Counterparty mix: mid‑market to large health systems. AMS sells to medium sized medical centers and large cancer networks through direct sales.
Capital intensity and spend bands: Gamma Knife facilities typically cost $3.0–$4.5 million, while single‑room PBRT systems cost $30–$50 million, indicating wide variance in customer spend and implementation complexity.
Concentration risk: Two customers represented ~35% and ~27% of 2024 revenue, and one customer accounted for 48% of 2023 revenue; revenue concentration is material.
Operational maturity and activity: As of December 31, 2024 the company leases nine Gamma Knife systems and one PBRT system, evidencing an active installed base across multiple U.S. states and select LATAM sites.

Explore deeper company signals and counterparty mapping at https://nullexposure.com/.

Relationship roster: contracts reported in public sources

The available reporting identifies two publicly announced customer placements that illustrate AMS’s go‑to‑market in practice.

Methodist Hospitals–Southlake Campus (Merrillville, Indiana)

American Shared Hospital Services announced a contract to supply a Gamma Knife Perfexion system to the Methodist Hospitals–Southlake Campus, consistent with AMS’s model of leasing high‑value radiosurgery equipment to regional hospitals. This placement demonstrates the company’s penetration into regional hospital systems and its reliance on device installations to generate fee‑per‑use revenue. Source: GreatNews.life press release reporting the FY2018 contract.

PeaceHealth Sacred Heart Medical Center at RiverBend (Springfield, Oregon)

AMS supplied a Gamma Knife Perfexion system to PeaceHealth Sacred Heart Medical Center at RiverBend, and physicians began treating patients with the system under AMS’s operational support model, reflecting the company’s provision of equipment plus clinical support to accelerate utilization. Source: ITN Online report referencing the FY2015 installation and patient treatments.

Each of these relationships is consistent with AMS’s strategy of placing Gamma Knife systems with regional and system hospitals and capturing procedure‑level economics through multi‑year leases and services.

What the contract and portfolio constraints tell investors

The company‑level constraint evidence provides a concise view of AMS’s operating model and risk profile:

Long‑term contractual commitments: The company’s typical fee‑per‑use leasing agreement is for a ten‑year term, which increases revenue visibility but also extends customer concentration and exposure over a decade.
Usage‑based revenue recognition: Fee‑per‑use and revenue‑sharing structures mean revenue is correlated directly to procedure volumes and hospital throughput; downturns or slower adoption at a site affect cash flows quickly.
Counterparty profile and market positioning: AMS targets both mid‑market medical centers and larger cancer networks, enabling a mix of steady smaller placements and occasional large, system‑level contracts.
Geographic footprint: The installed base and marketing efforts are primarily North American with select LATAM operations (single‑unit Gamma Knife facilities in Peru and Ecuador) and statements positioning AMS for global sales.
Material concentration risk: The firm reports large revenue concentration, with a small number of customers accounting for a majority of sales in recent years—this is a central credit and equity risk.
Service provider role and lock‑in: AMS provides equipment plus installation, reimbursement and marketing support, increasing customer dependence on AMS’s operational capabilities and creating switching friction.
Segment mix and ticket size: Revenue is split between hardware (equipment placement) and services (clinical throughput support) with spend bands ranging from a few million for Gamma Knife facilities to tens of millions for PBRT rooms.

These signals imply stable but concentrated recurring revenue, exposure to procedure demand cycles, and reliance on AMS’s ability to sign and operationalize long‑duration leases.

Investment implications and risks

Upside driver: If AMS grows procedure volumes across its installed base and signs additional ten‑year placements, the company benefits from recurring, usage‑linked cash flow and potential upside under revenue‑share contracts.
Key risks: Customer concentration creates single‑counterparty exposure; volume sensitivity means utilization declines will depress revenue quickly; capital deployment for PBRT scale‑ups requires execution and potential balance‑sheet management.
Operational moat: The combined offering of equipment placement plus reimbursement and commercialization support is a differentiator for hospitals that lack in‑house radiosurgery programs.

For detailed customer maps and financial linkage analysis, review the Null Exposure platform at https://nullexposure.com/.

Bottom line and next steps

American Shared Hospital Services operates as a specialized lessor/operator of high‑value radiosurgery equipment, generating revenue through long‑term, usage‑based contracts with materially concentrated customer exposure. For investors, the trade is between recurring, procedure‑linked upside and single‑name concentration and utilization risk — a profile that rewards rigorous counterparty monitoring and active portfolio management.

If you are evaluating AMS relationships or similar healthcare equipment finance exposures, explore additional profiles and lineage analysis on the Null Exposure homepage: https://nullexposure.com/. For a tailored report or customer concentration drill‑down, begin at https://nullexposure.com/ and request the AMS customer intelligence pack.